Aberrant expression of the PI3K/AKT/mTOR pathway is a frequent phenomenon in breast cancer and it is the result of a PIK3CA mutation, which corresponds to the PI3K p110 catalytic subunit, and more specifically to isoform α. This evidence concerns the gene AKT1 and breast cancer.